Verapamil: An Updated Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension

Drugs

Volumn 38, Issue 1, 1989, Pages 19-76

  McTavish, Donna ^a   Sorkin, Eugene M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CAPTOPRIL; DIURETIC AGENT; METOPROLOL; NIFEDIPINE; PINDOLOL; PRAZOSIN; PROPRANOLOL; VERAPAMIL;

AGE; ANGINA PECTORIS; BIOAVAILABILITY; BLOOD LEVEL; BRADYCARDIA; CALCIUM ANTAGONISM; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG METABOLISM; DRUG TOLERANCE; EXERCISE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION; VASODILATATION;

CLINICAL TRIALS; COMPARATIVE STUDY; HUMAN; HYPERTENSION; VERAPAMIL;

EID: 0024363416     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198938010-00003     Document Type: Article

References (390)

1. Lack of interaction between verapamil and cimetidine
2. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients: altered electrocardiographic and hypertensive responses
3. Verapamil and norverapamil determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single-dose pharmacokinetic studies
4. Inhibition of human platelet function by verapamil
5. Tachyphylaxis to verapamil
6. Reversal of cardiac hypertrophy by long-term treatment with calcium antagonists in hypertensive patients
7. Comparative effects of oral and inhaled verapamil on antigen-induced bronchoconstriction
8. Nicardipine and verapamil in essential hypertension
9. A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease
10. Excretion of verapamil in human milk
11. Pharmacokinetics of verapamil in patients with hypertension
12. Verapamil in hypertension: comparison of twice- and thrice-daily dosing on blood pressure and pharmacokinetics
13. Clinical pharmacokinetics of verapamil in patients with atrial fibrillation
14. Hypercalcemic and calcium-antagonistic effects on insulin release and oral glucose tolerance in man
15. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiological effects
16. Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration
17. Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapies
18. Combined therapy with verapamil and propranolol in chronic stable angina
19. Verapamil in chronic stable angina: a controlled study with computerised multistage treadmill exercise
20. Verapamil cardioplegia: improved myocardial preservation during global ischemia
21. Verapamil-rifampin interaction
22. Near-total reduction in verapamil bioavailability by rifampin
23. Calcium antagonists and hormone release. VI. Effects of a calcium antagonist (verapamil) on the biphasic insulin release in vivo
24. Interaction of verapamil with human platelet α-adrenergic receptors
25. Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition
26. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy
27. Calcium metabolism in essential hypertensive patients treated by verapamil
28. A controlled study of slow release verapamil in antihypertensive therapy
29. Treatment of tachycardic arrhythmias and arterial hypertension with verapamil
30. Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination
31. Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension
32. Verapamil in arterial hypertension with renal disease
33. Nebulised sodium cromoglycate and verapamil in methacholine induced asthma
34. Effects of verapamil and propranolol on left ventricular systolic function and diastolic filling in patients with coronary artery disease: radionuclide angiographic studies at rest and during exercise
35. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophie cardiomyopathy
36. Mechanism of action of calcium-channel-blocking agents
37. Klinisch-experimentelle Untersuchungen über die blutdrucksenkende wirkung von verapamil
38. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics
39. Influence of verapamil and oxygen on pulmonary hypertension and right ventricular function
40. The place of the calcium antagonist verapamil in antihypertensive therapy
41. Reduction of creatine kinase and creatine kinase-MB indexes of infarct size by intravenous verapamil
42. Hemodynamic effects of verapamil in left ventricular valvular volume overload
43. Hazards of intravenous verapamil for sustained ventricular tachycardia
44. Twenty-four-hour blood pressure monitoring after a single dose of sustained release verapamil
45. Effects of sustainedrelease verapamil on 24-hour ambulatory blood pressure and on pressor response to isometric exertion in hypertensive patients
46. Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients
47. Casual versus 24-hour ambulatory blood pressure recording in the evaluation of chronic administration of sustained-release verapamil
48. Effect of verapamil on normal sinoatrial node function and on sick sinus syndrome
49. Assessment of ‘once daily’ verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording
50. Acute intoxication with verapamil
51. Angiotensin converting enzyme inhibitor, diuretic, and calcium antagonist: a new tritherapy for severe arterial hypertension
52. Hypertension with orthostatic hypotension: interest of verapamil
53. Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action
54. Influence of the severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease
55. Antiplatelet effects of verapamil in man
56. Acute verapamil poisoning: successful treatment with epinephrine
57. Verapamil overdose
58. Exercise hemodynamics and oxygen delivery in human hypertension: response to verapamil
59. Isometric exercise before and after acute and chronic verapamil administration in controls and in hypertensives
60. Long term verapamil therapy in mild-to-moderate hypertension: randomised study of normal and slow-release formulations
61. Calcium antagonists and diuretics in arterial hypertension: a useful combination
62. Slow channel blockers
63. The antihypertensive efficacy of verapamil in the elderly evaluated by ambulatory blood pressure measurement
64. Treating hypertension in black compared with white non-insulin dependent diabetics: a double-blind trial of verapamil and metoprolol
65. A comparison of verapamil and propranolol for the initial treatment of hypertension
66. Comparative pharmacokinetics and pharmacodynamics of IR and SR verapamil in patients with hypertension: effects of food intake
67. Verapamil in acute myocardial infarction
68. Abrupt withdrawal of verapamil in ischaemic heart disease
69. Verapamil and beta-blockers in hypertension: a beneficial drug interaction?
70. The effects of various antihypertensives on blood lipids
71. Acute and chronic effects of verapamil in exercise-induced angina
72. Effect of nifedipine and verapamil on carbohydrate metabolism in hypertensive patients with impaired glucose tolerance
73. Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram
74. Effect of coadministration of verapamil and quinidine on serum digoxin clearance
75. The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration
76. Verapamil concentrations in cerebrospinal fluid after oral administration
77. Comparison of beta-adrenoceptor blockers and calcium antagonists in hypertension
78. Verapamil — a once-daily dosage: pharmacokinetic and pharmacodynamic observation
79. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem
80. Effects of d,l-vera-pamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism
81. Twenty-four-hour monitoring of blood pressure during calcium antagonist therapy
82. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine
83. Clinical pharmacology of calcium channel blockers
84. Effects of verapamil on P-R intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment
85. 14C-D-L-verapamil in man
86. Pharmacokinetics of (+)-, (−)- and (± )-verapamil after intravenous administration
87. Inter-and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing: studies with deuterated verapamil
88. Dengler HJ. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of d,l-verapamil using stable isotopelabelled verapamil
89. Verapamil sustained-release in renal parenchymal hypertension; effect on blood pressure, kidney function, angiotensin II, aldosterone, arginine vasopressin, atrial natriuretic peptide, and lipoproteins
90. Verapamil and prazosin in essential hypertension: evidence of a synergistic combination?
91. Verapamil in Duchenne muscular dystrophy
92. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia
93. Pharmacokinetics of chronic oral verapamil therapy in infants
94. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy
95. Factors influencing the hypotensive effects of calcium antagonists
96. Comparative study of the antihypertensive effect of verapamil and atenolol
97. Hyperprolactinemia-galactorrhoea induced by verapamil
98. Verapamil: a multicentre hospital trial in the treatment of hypertension
99. Use of verapamil for paroxysmal supraventricular tachycardia during epidural anesthesia for cesarean section
100. Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure
101. Effects of verapamil on myocardial performance in coronary disease
102. Antianginal and myocardial metabolic properties of verapamil in coronary artery disease
103. Effect of verapamil on glucose, insulin and glucagon levels after oral glucose load in normal and diabetic subjects
104. Effects on cardiac function, heart rate and blood pressure during combination therapy with verapamil and atenolol
105. Verapamil pharmacokinetics and liver function in patients with cirrhosis
106. Effects of the calcium channel blocker, verapamil on asthmatic airway responses to muscarinic, histaminergic, and allergic stimuli
107. Differential effects of calcium channel blocking agents on oxygen consumption rate in vascular smooth muscle
108. Consequences of uncontrolled calcium entry and its prevention with calcium antagonists
109. ++-antagonistischer. Inhibitor de elektro-mechanischen Koppelungsprozesse im warmblütermyokard
110. Verapamil kinetics in normal subjects and patients with coronary artery spasm
111. Effect of isosorbide dinitrate, verapamil and labetalol on portal pressure in cirrhosis
112. Hemodynamics of hypertension
113. Verapamil in the treatment of chronic stable angina
114. Twice-daily administration of oral verapamil in the treatment of essential hypertension
115. Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension
116. Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris: a placebo-controlled double blind randomised crossover trial
117. Electropharmacology of the slow-channel inhibitors in the management of cardiac arrhythmias: verapamil
118. Re-examination of the hemodynamics of hypertension
119. Fatal poisoning with verapamil
120. Decreased binding of verapamil to plasma proteins in patients with liver disease
121. Verapamil-induced hyperprolactinemia and galactorrhea
122. Treatment of severe verapamil poisoning with combined amrinone-isoproterenol therapy
123. Relationships between verapamil plasma concentrations and its antihypertensive action
124. Calcium entry blockers and human platelet aggregation
125. The 24-hour intra-arterial ambulatory profile of blood pressure reduction with verapamil
126. Reassessing portal venous pressure measurements
127. Liver damage from verapamil
128. Verapamil: full spectrum calcium channel blocking agent: an overview
129. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil
130. Application of Iproveratril in the pharmacotherapy of hypertension
131. Verapamil and propranolol in essential hypertension
132. Clinical pharmacokinetics of verapamil
133. Inhibition of platelet function by antiarrhythmic drugs, verapamil and disopyramide
134. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients
135. Verapamil hepatotoxicity: a hypersensitive reaction
136. Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White Syndrome
137. The effects of verapamil and propranolol on quality of life in hypertension
138. The combination of verapamil and captopril in the treatment of essential hypertension
139. Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension
140. The antihypertensive effect of verapamil in twice and thrice daily dose regimens: a randomized, double-blind, crossover trial
141. Sustained-release verapamil or atenolol in essential hypertension
142. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem
143. Does verapamil improve left ventricular relaxation in patients with myocardial hypertrophy?
144. Verapamil and myoclonic dystonia
145. Verapamil-potassium cardioplegia: a two-year experience with 470 patients
146. Verapamil potassium cardioplegia and cardiac conduction
147. Pharmacokinetics and pharmacodynamics of two formulations of verapamil
148. Comparison of equivalent oral doses of verapamil and diltiazem in patients with mild to moderate hypertension
149. Pharmacodynamic and pharmacokinetic interaction of flecainide and verapamil
150. Electrophysiologic effects of nicardipine hydrochloride (YC-93) on the human cardiac conduction system
151. Twice-daily verapamil for hypertension: a comparison with propranolol
152. Verapamil in essential hypertension: a comparison with atenolol plus hydralazine
153. The effects of age on the pharmacokinetics and pharmacodynamics of two formulations of verapamil
154. Efficacy of verapamil-hydrochlorothiazide-spironolactone therapy in hypertensive black patients
155. Action of verapamil on sinus node atrioventricular and intraventricular conduction
156. β-blockers and verapamil: a cautionary tale
157. Liquid-chromatographic quantification compared with gas-chromatographic-mass spectrometric determination of verapamil and norverapamil in plasma
158. Inhibition of human platelet functions by verapamil
159. Three cases of severe verapamil poisoning
160. Level of verapamil in human milk
161. Delirium induced by verapamil
162. The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics
163. 2-induced aggregation of human platelets
164. A comparison of verapamil and nifedipine in patients with Prinz-metal’s variant angina pectoris
165. Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: a double-blind, placebo-controlled, randomised, crossover study with radionuclide ventriculography
166. Clinical and haemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomised crossover study
167. Twice-daily dosing of verapamil in hypertension
168. Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies
169. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations
170. Verapamil disposition kinetics in chronic atrial fibrillation
171. Comparative effects of three calcium antagonists; diltiazem, verapamil, and nifedipine, on the sinoatrial and atrioventricular nodes: experimental and clinical studies
172. Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man
173. Verapamil protein binding in patients and in normal subjects
174. The effect of verapamil on the pharmacokinetics of adriamycin
175. Impotence during therapy with verapamil
176. Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists
177. Pharmacokinetics of a verapamil slow release formulation
178. Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction
179. Verapamil-digoxin interaction
180. The influence of verapamil on serum digoxin concentration
181. Treatment of angina pectoris and hypertension with sustained-release calcium channel blocking drugs
182. The influence of long-term therapy with verapamil on the development of coronary artery stenosis
183. Can the progression of coronary sclerosis be influenced by calcium antagonists?
184. Pharmacokinetics of verapamil in man
185. The haemodynamic effect of verapamil on portal hypertension in patients with postnecrotic cirrhosis
186. Accentuated negative inotropism of verapamil after ischaemic intervention in isolated working rat heart
187. Asystole after verapamil and digoxin
188. Poisoning with sustained-release verapamil
189. Sustained-release verapamil in the treatment of hypertensive patients with impaired renal function
190. The effects of verapamil on renal blood flow, renal function, and neuro-hormonal profiles in patients with moderate to severe hypertension
191. Effects of quinidine, verapamil and nifedipine on the pharmacokinetics and pharmacodynamics of digitoxin during steady state conditions
192. Bradyarrhythmia induced by orally administered verapamil and propranolol in chronic hemodialysis patients
193. Bizarre perceptual disorder of extremities in patients taking verapamil
194. Calcium metabolism, calcium-channel blocking agents, and hypertension management
195. Effects of verapamil on estimated hepatic blood flow in patients with HBsAg-positive cirrhosis
196. Comparison of sustained release verapamil and hydrochlorothiazide in hypertension — effect on blood pressure and metabolic variables
197. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris
198. Comparison of cardiovascular, renal, and humoral effects of acute administration of the calcium channel blockers in normotensive and hypertensive subjects
199. Verapamil and propranolol: a comparison of two hypertensive agents
200. Anti-hypertensive and renal effects of orally administered verapamil
201. Combined administration of verapamil and beta blockers in patients with angina pectoris
202. Immediate hemodynamic effects of verapamil in man
203. Verapamil in the management of chronic hypertension
204. The long-term management of hypertension with verapamil
205. The treatment of hypertension with verapamil
206. Adverse reactions to calcium antagonists
207. Verapamil inhibits cyclosporin metabolism
208. Effect of cimetidine on verapamil disposition
209. Verapamil-neostigmine interaction?
210. Efficacy of verapamil in patients resistant to other antihypertensive therapy
211. Hemodynamic effects of verapamil in essential hypertension at rest and during exercise
212. Hemodynamic effects of calcium channel blockers at rest and during exercise in essential hypertension
213. Diuretics and calcium antagonists in hypertension
214. Clinically relevant adverse interaction between verapamil and carbamazepine in epileptic patients
215. Diltiazem and verapamil: functional antagonism of exogenous noradrenalin and angiotensin II in man
216. Hypotension after quinidine plus verapamil
217. Long-term verapamil therapy in primary congestive cardiomyopathy
218. Calcium antagonists: basic chemical and pharmacological properties
219. Verapamil-induced changes in digoxin kinetics in cirrhosis
220. Verapamil in prophylactic therapy of migraine
221. Long-term treatment of primary hypertension with verapamil
222. Acute intoxication with verapamil treated by dobutamine and endocavitary stimulation [Intoxication aìguè par le vérapamil traitée par dobutamine et stimulation endocavitaire]
223. Effects of nicardipine hydrochloride on the conduction system of the heart in man
224. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state
225. Serum lipids in hypertensive patients treated with verapamil
226. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses
227. Kinetics and dynamics of calcium entry antagonists in systemic hypertension
228. Calcium in the pathogenesis and therapy of human hypertension
229. The clinical use of verapamil
230. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White Syndrome
231. 1-acid glycoprotein and drug efficacy
232. Clinical pharmacology of verapamil
233. Celiprolol and verapamil in the treatment of essential hypertension
234. Intravenous verapamil during β-adrenoceptor blockade with propranolol
235. Effects of verapamil on platelet aggregation, ATP release and thromboxane generation
236. Verapamil pharmacokinetics and apparent hepatic and renal blood flow
237. Prazosin and verapamil: a pharmacokinetic and pharmacodynamic interaction?
238. The calcium-channel blocker verapamil does not improve portal pressure in patients with alcoholic cirrhosis
239. Verapamil in the treatment of hypertension
240. Influence of verapamil and nifedipine on the pressor response to isometric exertion in hypertensive patients
241. A new sustained-release formulation of verapamil in the treatment of hypertension
242. Once and twice daily administration of verapamil retard in the treatment of essential hypertension
243. Double-blind comparison of the antihypertensive effects of verapamil and nifedipine
244. No metabolic side effects of long-term treatment with verapamil in hypertension
245. Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms
246. Verapamil and breastfeeding
247. Sinus arrest caused by atenololverapamil combination
248. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review
249. Cardiac arrest following I.V. verapamil combined with halothane anaesthesia
250. The influence of antituberculosis drugs on the plasma level of verapamil
251. Pharmacokinetics of verapamil in patients with renal failure
252. The effects of verapamil and propranolol on exercise tolerance in hypertensive patients
253. Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension
254. Pharmacokinetics of once-daily verapamil: comparative bioavailability of two sustained-release formulations
255. Calcium antagonists and the second drug for hypertensive therapy
256. Once a day verapamil in essential hypertension
257. Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia
258. Hepatic injury possibly induced by verapamil
259. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension
260. Calcium antagonists and the ischemic myocardium
261. Calcium antagonists and hypertension
262. Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and perfused myocardium
263. Calcium entry blockers and myocardial function
264. Severe liver injury possibly due to verapamil
265. Improvement of the quantitative determination of verapamil in human plasma
266. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetized dog
267. The antihypertensive effect of verapamil at extremes of dietary sodium intake
268. Hydrochlorothiazide is not additive to verapamil in treating essential hypertension
269. Effects of verapamil on exocrine pancreatic secretion in man
270. Sustained release verapamil in hypertension: results from a noninvasive ambulatory blood pressure monitoring and clinical study
271. A multicenter study of verapamil in systemic hypertension in Thailand
272. The bioavailability of a slow-release verapamil formulation
273. A controlled clinical trial of verapamil in the treatment of hypertension: comparison with alpha methyldopa
274. Drugs and the heart, III: calcium antagonists
275. Calcium antagonists — mechanisms, therapeutic indications and reservations: a review
276. Calcium channel antagonists. Part III: use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications
277. Calcium and catecholamines: relevance to cardiomyopathies and significance in therapeutic strategies
278. Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, β-blockers, and nitrates on atherosclerotic characteristics of human aortic cells
279. Treatment of hypertension during pregnancy with the calcium antagonist verapamil
280. Fatal verapamil overdose
281. Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris
282. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease
283. Detrimental effects of verapamil in patients with primary pulmonary hypertension
284. Modification of experimental atherosclerosis by calcium-channel blockers
285. Management of unstable angina at rest by verapamil: a double-blind cross-over study in coronary care unit
286. Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects
287. A combination of verapamil, captopril, and diuretic in the treatment of severe hypertension
288. The effect of inhaled verapamil on allergen-induced bronchoconstriction
289. Comparison of two calcium antagonists, verapamil and gallopamil (D-600), in exercise-induced asthma
290. Verapamil-induced changes in digoxin kinetics and intraerythrocytic sodium concentration
291. Digoxin-verapamil interaction
292. Interference of calcium entry blockade i nv ivowith pressor responses to α-adrenergic stimulation: effects of two unrelated blockers on responses to both exogenous and endogenously released norepinephrine
293. Plasma lipid profile in verapamiltreated hypertensive patients
294. Effect of diltiazem in patients with variant angina: a randomised double-blind trial
295. The effect of verapamil on cardiovascular and metabolic responses to exercise
296. Determination of verapamil and its primary metabolites in serum by ion-pair adsorption high-performance liquid chromatography
297. The effect of inhaled verapamil on resting bronchial tone and airway contractions induced by histamine and acetylcholine in normal and asthmatic subjects
298. Antihypertensive effect of verapamil. Results with a new sustained-release formulation for once daily administration
299. Neurotoxicity caused by lithium-vera-pamil synergism
300. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction
301. Bradycardia after verapamil and spinal analgesia
302. Verapamil and supraventricular tachyarrhythmias: beneficial effect in patients with chronic pulmonary disease
303. Side effects of verapamil in infants
304. Verapamil in the long-term treatment of angina pectoris
305. Calcium antagonists in the treatment of hypertension. An overview
306. Clinical pharmacological studies on the interaction between α-adrenoceptors and calcium antagonists
307. Verapamil SR 240mg as a contribution to compliance in long-term treatment of hypertension
308. Comparison of intravenous and oral verapamil dosing
309. Com-parative effects of verapamil and isradipine on steady-statdigoxin kinetics
310. Does verapamil influence glucose-induced insulin release in man?
311. Effectiveness of verapamil in the prevention of ventricular fibrillation in the acute stage of myocardial infarction
312. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy
313. Primary pulmonary hypertension
314. Mechanism of relief of pacing-induced angina with oral verapamil: reduced oxygen demand
315. Hyperkalemia, verapamil and dantrolene
316. Effects of chronic phenobarbital on verapamil disposition in humans
317. Cerebral infarction associated with oral verapamil overdose
318. The treatment of renal hypertension with verapamil in childhood
319. Cardiovascular effects of verapamil in patients with essential hypertension
320. Studies on the disposition of verapamil in patients with renal failure
321. Physiologic disposition of verapamil in man
322. Serum concentration and antihypertensive effect of slow release verapamil
323. Verapamil pharmacokinetics
324. An investigation of the cause of accumulation of verapamil during regular dosing in patients
325. Hemodynamic effects of verapamil and practolol in man
326. Plasma levels of verapamil and its effects on blood pressure, body fluid volumes and renal function in hypertensive patients
327. Antihypertensive effect of verapamil in severe pre-eclampsia —a preliminary study
328. Verapamil kinetics during maintenance hemodialysis
329. Influence of oral verapamil on glucoregulatory hormones in man
330. Reduced verapamil clearance during long-term oral administration
331. The effect of verapamil inhalation on pulmonary functions in bronchial asthma
332. Studies with sustained-release verapamil in essential hypertension
333. The effects on left ventricular performance of nifedipine and verapamil in exercise-induced angina pectoris
334. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil
335. New perspectives in the pharmacologic therapy of cardiac arrhythmias
336. Verapamil: a review of its pharmacological properties and therapeutic use
337. Calcium antagonists: clinical use in the treatment of arrhythmias
338. Calcium antagonists and beta blockers in the control of mild to moderate systemic hypertension, with particular reference to verapamil and propranolol
339. Effects of intravenous verapamil on hemodynamics in patients with heart disease
340. Effect of calcium channel antagonists on theophylline disposition
341. The influence of cimetidine on the pharmacokinetics and the pharmacodynamics of verapamil
342. Verapamil prophylaxis of migraine
343. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis
344. Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension
345. The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease: a review
346. Efficacy and safety of Isoptin® SR 240mg in essential hypertension — results of a phase IV study under practice conditions
347. Determination of verapamil in human plasma by mass fragmentography using stable isotopelabelled verapamil as internal standard
348. Treatment of resistant hypertension: 3 years of follow-up with the combination of verapamil and methyldopa
349. The effect of verapamil on the electrophysiological properties of the anomalous atrioventricular connections in Wolff-Parkinson-White syndrome
350. Cardiovascular effects of verapamil in essential hypertension
351. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II. Hemodynamic effects and clinical applications
352. The determination of verapamil in maternal and fetal blood
353. Calcium antagonists: clinical use in the treatment of angina
354. Electrophysiological effects of quinidine alone and of the combination quinidine-verapamil on AV conduction in humans
355. Measurement of verapamil concentrations in plasma by gas chromatography and high pressure liquid chromatography
356. Increased quinidine plasma concentrations during administration of verapamil: a new quinidine-verapamil interaction
357. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review
358. Intrauterine conversion of fetal supraventricular tachycardia with combination of digoxin and verapamil
359. Parenteral-verapamil-induced sustained hypotension
360. Fatal acute intoxication with verapamil
361. Effect of calcium channel blockade and beta-adrenoceptor blockade on short graded and single-level endurance exercises in normal men
362. Verapamil and reversal of vercuronium neuromuscular blockade
363. Gaschromatographic determination of verapamil and norverapamil, with a nitrogen-selective detector
364. Verapamil slow release tablets: kinetic and dynamic properties in healthy volunteers
365. Effect of verapamil on left ventricular function: a randomised placebo-controlled study
366. Stereo-selective first-pass metabolism of highly cleared drugs: studies of this bioavailability of (−)- and (+)-verapamil examined with a stable isotope technique
367. Comparison of betaxolol with verapamil in hypertensive patients: discrepancy between office and ambulatory blood pressures
368. Differential effects of systemic and intracoronary calcium channel blocking agents on global and regional left ventricular function in conscious dogs
369. Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol
370. Calcium channel blockers
371. Decreased serum lithium during verapamil therapy
372. Short and long term treatment of mild to moderate hypertension with verapamil
373. Verapamil disposition — effects of sulphinpyrazone and cimetidine
374. Hemodynamic and electrophysiologic effects of verapamil and nifedipine in patients on propranolol
375. Verapamil and norver-apamil plasma concentrations during long-term therapy in patients with hypertrophic obstructive cardiomyopathy
376. Verapamil disposition in liver disease and intensive care patients: kinetics clearance and apparent blood flow relationships
377. Verapamil in healthy volunteers after single oral and sublingual administration
378. Factors affecting the plasma protein binding of verapamil and norverapamil in man
379. Antihypertensive efficacy of sustained-release verapamil
380. Verapamil-digoxin interaction
381. Verapamil in hypertension: a long-term study
382. Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog
383. New antiarrhythmic agents
384. Verapamil overdose: report of a case and review of the literature
385. Profound bradycardia with verapamil and halothane